Document Type

Article

Publication Date

1-1-2024

Keywords

JGM, Humans, Neoplasms, Child, Stem Cells, Models, Biological

JAX Source

Cancer Control. 2024;31:10732748241270564.

ISSN

1526-2359

PMID

39118322

DOI

https://doi.org/10.1177/10732748241270564

Grant

This work 8 Cancer Control was supported by the CCMC Martin J Gavin Endowment, West Family Trust, JAX Director Innovation Fund, National Human Genome Research Institute (NHGRI) (5T32HG010463-05), Cur- eSearch for Childrens Cancer (685676) and Congressionally Directed Medical Research Program (W81XWH-22-1-0177).

Abstract

Despite improvements in patient outcomes, pediatric cancer remains a leading cause of non-accidental death in children. Recent genetic analysis of patients with pediatric cancers indicates an important role for both germline genetic predisposition and cancer-specific somatic driver mutations. Increasingly, evidence demonstrates that the developmental timepoint at which the cancer cell-of-origin transforms is critical to tumor identity and therapeutic response. Therefore, future therapeutic development would be bolstered by the use of disease models that faithfully recapitulate the genetic context, cell-of-origin, and developmental window of vulnerability in pediatric cancers. Human stem cells have the potential to incorporate all of these characteristics into a pediatric cancer model, while serving as a platform for rapid genetic and pharmacological testing. In this review, we describe how human stem cells have been used to model pediatric cancers and how these models compare to other pediatric cancer model modalities.

Creative Commons License

Creative Commons Attribution-NonCommercial 4.0 International License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Share

COinS